Clinical Trial Update: Study on MK-3475 Plus Chemotherapy Versus Chemotherapy Alone in Recurrent, Platinum-resistant Ovarian Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating pembrolizumab (Keytruda) plus chemotherapy versus chemotherapy alone in recurrent platinum-resistant ovarian cancer. The trial status…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• KEYTRUDA (PEMBROLIZUMAB)

Snippet

Sponsor: Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | Conditions: Ovarian Cancer | Phase 2 | Status: UNKNOWN